

Next Science appoints Grace Medical as exclusive distributor of Sinus Lavage in USA, Europe, Australia & other key markets

Sydney, Australia, Monday, 27 May 2019: Australian medical technology company, Next Science Limited (ASX: NXS) (**Next Science**), today announces that it has appointed US-based Grace Medical, a recognised global market leader in the ear, nose and throat (**ENT**) marketplace, as an exclusive distributor of Next Science's Sinus Lavage.

Grace Medical offers an extensive range of products for use in ENT procedures and has agreed to commence distribution of Next Science's Sinus Lavage via its extensive networks throughout the United States, Europe, Australia and other key markets, following receipt of the required regulatory clearance for the product. Under the agreement, Next Science appoints Grace Medical as its exclusive distributor to promote, market, distribute and sell Sinus Lavage for use as a medical device in human rhinology and airway procedures.

Next Science expects to submit the Sinus Lavage for FDA approval through the 510(k) pathway, and for CE Mark approval, in 2019.

An estimated 40 million people in the USA and 35 million people in Western Europe have Chronic Rhinosinusitis (**CRS**).¹ In the US, about 1.3 million people seek out an ENT specialist for treatment, with about 550,000 opting for Functional Endoscopic Sinus Surgery (**FESS**) typically once medical management of CRS has failed. A relatively new alternative procedure, balloon sinusplasty, which is a less invasive procedure, is also gaining in popularity.

These procedures, although effective, do not address the problem of biofilm in CRS. Microbial biofilms have been implicated as a cause of recalcitrant CRS. In the case of CRS patients, biofilms may also be a significant factor in stronger inflammatory response that perpetuates the sinusitis symptoms. Independent research has shown that biofilms are one of the leading causes of antibiotic failure in CRS patients. In several studies, biofilms have been shown to be prevalent in anywhere from 45 -100% of CRS patients.²

Next Science's Sinus Lavage, using Xbio™ technology, is designed to be used (subject to regulatory approvals being obtained) as an adjunct to both FESS and balloon sinusplasty procedures to aid in washing away and removal of debris, including microorganisms from the sinus cavities.

Next Science CEO, Judith Mitchell, said: "We are excited about our new partnership with Grace Medical as it represents a major step towards our unique ENT solutions being adopted, over time, as a component of a new standard of care in ENT healthcare in these key markets. We strongly believe that the Sinus Lavage will help to improve clinical outcomes for patients who are adversely affected by chronic sinusitis.

¹ Hamilos DL, J Allergy Clin Immunol. 2011 Oct; 128(4): 693-707; Hastan et al, Allergy Vol 66, Issue 9, Sept 2011 p1216-1223

² Fastenberg J et al World Journal of Otorhinolaryngology – Head and Neck Surgery (2016) 2, 219e229

NEXT SCIENCE®

We take pride in the science underpinning our products and the impact our products can have on people under medical care. We actively seek partners for our products who will help us reach those patients most in need.”

While Grace Medical has committed to meeting stipulated performance criteria, Next Science has maintained flexibility should Grace Medical not meet these measures within specified timeframes.

The five (5) year distribution agreement commences upon the date Next Science first obtains regulatory approval for Sinus Lavage in any country within the territory granted to Grace Medical. It will automatically renew thereafter for successive 5 year periods subject to either party having a right to terminate on six months’ written notice before the end of the initial term or any subsequent term and various other events which entitle a party to terminate.

- - - END - - -

For further information, please contact:

Investor inquiries

Judith Mitchell, Managing Director

Phone: +61 2 9375 7989

Email: investorqueries@nextscience.com

Partnering inquiries

Byron Darroch, Executive VP, Partnerships

Phone: +61 2 8607 5124

Email: bdarroch@nextscience.com

About Next Science

Next Science is a medical technology company headquartered in Sydney, Australia, with a research and development centre in Florida, USA. Established in 2012, the Company’s primary focus is on the development and continued commercialisation of its proprietary Xbio™ technology to reduce the impact of biofilm based infections in human health. Xbio is a unique, non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Next Science owns 100% of the patent protected intellectual property relating to its Xbio technology.

For further information visit: www.nextscience.com.